Dashboard
Manage Tickers

XGNEXAGEN INC.

Nasdaq exagen.com


$ 3.06 $ 0.08 (2.71 %)    

Wednesday, 11-Sep-2024 15:59:38 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 468.85 $ 0.22 (0.05 %)
DIA $ 409.07 $ -0.39 (-0.1 %)
SPY $ 554.63 $ -0.36 (-0.06 %)
TLT $ 100.24 $ -0.13 (-0.13 %)
GLD $ 235.37 $ 0.73 (0.31 %)
$ 3.03
$ 3.05 x 100
-- x --
-- - --
$ 1.30 - $ 3.71
44,056
na
52.68M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-18-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-20-2023 12-31-2022 10-K
8 11-21-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-22-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-11-2021 03-31-2021 10-Q
15 03-16-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 07-28-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-25-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

exagen-increases-fy24-revenue-outlook-to-at-least-57m-vs-prior-outlook-of-at-least-55m-estimate-5575m
Exagen Increases FY24 Revenue Outlook To A...
08/05/2024 12:05:30

Given continued improved performance, now believes adjusted EBITDA loss will be better than $12 million versus prior oulook of ...

exagen-q2-2024-gaap-eps-016-beats-034-estimate-sales-15064m-beat-13133m-estimate
Exagen Q2 2024 GAAP EPS $(0.16) Beats $(0....
08/05/2024 12:01:39

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 52.9...

exagen-appoints-jeffrey-g-black-as-new-chief-financial-officer-effective-september-1-2024
Exagen Appoints Jeffrey G. Black As New Ch...
08/01/2024 13:15:40

Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Blac...

cantor-fitzgerald-maintains-overweight-on-exagen-raises-price-target-to-7
Cantor Fitzgerald Maintains Overweight on ...
05/14/2024 12:48:37

Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $5 to...

exagen-increases-fy24-revenue-to-at-least-55m-vs-54160m-est
Exagen Increases FY24 Revenue To At Least ...
05/13/2024 12:46:31

exagen-q1-2024-gaap-eps-019-beats-036-estimate-sales-14415m-beat-13095m-estimate
Exagen Q1 2024 GAAP EPS $(0.19) Beats $(0....
05/13/2024 12:14:45

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.2...

exagen-expects-q1-fy2024-revenue-of-13m-135m-versus-consensus-of-1149m-the-company-says-existing-cash-and-cash-equivalents-of-365m-will-be-adequate-to-meet-anticipated-cash-requirements-into-2026
Exagen Expects Q1 FY2024 Revenue Of $13M-$...
03/18/2024 12:09:20

exagen-expects-fy2024-revenue-of-approximately-54m-versus-consensus-of-5414m-for-fy2024-the-company-expects-adjusted-ebitda-will-be-better-than-negative-20m
Exagen Expects FY2024 Revenue Of Approxima...
03/18/2024 12:07:34

exagen-q4-gaap-eps-031-beats-043-estimate-sales-1377m-beat-1156m-estimate
Exagen Q4 GAAP EPS $(0.31) Beats $(0.43) E...
03/18/2024 12:03:06

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.9...

earnings-scheduled-for-march-18-2024
Earnings Scheduled For March 18, 2024
03/18/2024 09:57:15

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

earnings-outlook-for-exagen
Earnings Outlook For Exagen
03/15/2024 15:00:25

exagen-inc-announces-select-preliminary-full-year-2023-results-cash-balance-of-365m-as-of-december-31-2023-reaffirms-fy23-revenue-guidance-of-at-least-50m-vs-5043m-est
Exagen Inc. Announces Select Preliminary F...
01/07/2024 20:13:23

Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited fina...

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
01/05/2024 13:05:58

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
01/04/2024 21:31:07

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
12/01/2023 13:06:46

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
11/21/2023 21:31:06

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
11/20/2023 21:31:10

exagen-inc-entered-into-amendment-no-1-to-that-certain-sales-agreement-dated-september-15-2022-may-from-time-to-time-continue-to-issue-sell-shares-of-common-stock-having-an-aggregate-offering-price-of-up-to-50m
Exagen Inc Entered Into Amendment No. 1 To...
11/17/2023 21:38:57

- SEC Filing  

exagen-inc-files-for-mixed-shelf-of-up-to-150m
Exagen Inc Files For Mixed Shelf Of Up To ...
11/17/2023 21:12:18

- SEC Filing

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
11/15/2023 21:31:03

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION